PE20211887A1 - Receptor antigenico quimerico (car) que comprende un dominio de union a antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t - Google Patents
Receptor antigenico quimerico (car) que comprende un dominio de union a antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas tInfo
- Publication number
- PE20211887A1 PE20211887A1 PE2021000759A PE2021000759A PE20211887A1 PE 20211887 A1 PE20211887 A1 PE 20211887A1 PE 2021000759 A PE2021000759 A PE 2021000759A PE 2021000759 A PE2021000759 A PE 2021000759A PE 20211887 A1 PE20211887 A1 PE 20211887A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- trbc2
- trbc1
- joines
- antigenic
- Prior art date
Links
- 101000662909 Homo sapiens T cell receptor beta constant 1 Proteins 0.000 title abstract 2
- 101000662902 Homo sapiens T cell receptor beta constant 2 Proteins 0.000 title abstract 2
- 102100037272 T cell receptor beta constant 1 Human genes 0.000 title abstract 2
- 102100037298 T cell receptor beta constant 2 Human genes 0.000 title abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 230000000890 antigenic effect Effects 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 208000000389 T-cell leukemia Diseases 0.000 abstract 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 abstract 1
- 206010042971 T-cell lymphoma Diseases 0.000 abstract 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Virology (AREA)
Abstract
La presente invencion se refiere a un anticuerpo conjugado que tiene: i) una cadena pesada variable (VH) que comprende las siguientes regiones determinantes de complementariedad (CDR): VH CDR1 de SEQ ID NO: 7, VH CDR2 de SEQ ID NO: 8 y VH CDR3 de SEQ ID NO:9, ii) una cadena ligera variable (VL) que comprende las siguientes regiones determinantes de complementariedad (CDR): VL CDR1 de SEQ ID NO: 10, VL CDR2 de SEQ ID NO:11 y VL CDR3 de SEQ ID NO: 12, iii) una cadena pesada variable de SEQ ID NO: 1, iv) una cadena ligera variable (VL) de SEQ ID NO: 2 y v) un scFv de SEQ ID NO: 3. Tambien se refiere a una composicion que los comprende. Dicho anticuerpo se une selectivamente a la region TCR beta 1 (TRBC1) o TRBC2, siendo utiles en el tratamiento de linfoma o leucemia de celulas T.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201403905A GB201403905D0 (en) | 2014-03-05 | 2014-03-05 | Method |
| GB201416908A GB201416908D0 (en) | 2014-09-25 | 2014-09-25 | Method |
| PCT/GB2015/050643 WO2015132598A1 (en) | 2014-03-05 | 2015-03-05 | Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211887A1 true PE20211887A1 (es) | 2021-09-22 |
Family
ID=52649058
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016001548A PE20170125A1 (es) | 2014-03-05 | 2015-03-05 | Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t |
| PE2021000759A PE20211887A1 (es) | 2014-03-05 | 2015-03-05 | Receptor antigenico quimerico (car) que comprende un dominio de union a antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016001548A PE20170125A1 (es) | 2014-03-05 | 2015-03-05 | Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20170066827A1 (es) |
| EP (2) | EP3241561A1 (es) |
| JP (5) | JP6767872B2 (es) |
| KR (3) | KR102235202B1 (es) |
| CN (4) | CN106068276B (es) |
| AU (3) | AU2015225944B2 (es) |
| BR (1) | BR112016020304B1 (es) |
| CA (1) | CA2940564C (es) |
| CL (4) | CL2016002195A1 (es) |
| CU (1) | CU24475B1 (es) |
| DK (1) | DK3125934T3 (es) |
| ES (1) | ES2758173T3 (es) |
| HU (1) | HUE047641T2 (es) |
| IL (3) | IL278878B (es) |
| MX (3) | MX2016010856A (es) |
| MY (1) | MY173567A (es) |
| PE (2) | PE20170125A1 (es) |
| PH (2) | PH12016501646A1 (es) |
| PL (1) | PL3125934T3 (es) |
| PT (1) | PT3125934T (es) |
| RU (3) | RU2018140694A (es) |
| SG (3) | SG10201906461SA (es) |
| WO (1) | WO2015132598A1 (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11982672B2 (en) | 2014-03-05 | 2024-05-14 | Autolus Limited | Methods |
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| EP3868388A1 (en) * | 2014-10-03 | 2021-08-25 | Oxford University Innovation Limited | Analysis of t-cell monotypia |
| CA2937157A1 (en) * | 2016-07-25 | 2018-01-25 | Ucl Business Plc | Protein-based t-cell receptor knockdown |
| CA3221995C (en) | 2017-02-08 | 2024-05-28 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CA3054079A1 (en) | 2017-02-20 | 2018-08-23 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| PE20200006A1 (es) * | 2017-04-04 | 2020-01-06 | Hoffmann La Roche | Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap |
| GB201709203D0 (en) | 2017-06-09 | 2017-07-26 | Autolus Ltd | Antigen-binding domain |
| WO2019025800A1 (en) * | 2017-08-02 | 2019-02-07 | Autolus Limited | CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE |
| BR112020003654A2 (pt) * | 2017-08-23 | 2020-11-17 | Dragonfly Therapeutics, Inc. | proteínas de ligação ao nkg2d, cd16 e a um antígeno associado a tumor |
| JP7372920B2 (ja) * | 2017-12-29 | 2023-11-01 | セレクティス | Ｃａｒ ｔ細胞の作製を改良するための方法 |
| WO2019129850A1 (en) * | 2017-12-29 | 2019-07-04 | Cellectis | Off-the-shelf engineered cells for therapy |
| GB201800298D0 (en) * | 2018-01-09 | 2018-02-21 | Autolus Ltd | Method |
| US20200339687A1 (en) * | 2018-01-19 | 2020-10-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting gamma delta t cells with chimeric antigen receptors |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| US20210283180A1 (en) * | 2018-07-06 | 2021-09-16 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Car t cell therapy to target t cell specific cancers |
| WO2020018708A1 (en) * | 2018-07-18 | 2020-01-23 | The General Hospital Corporation | Compositions and methods for treatment of t cell malignancies |
| GB201812650D0 (en) * | 2018-08-03 | 2018-09-19 | Autolus Ltd | Molecular assessment of TRBC usage |
| GB201817172D0 (en) | 2018-10-22 | 2018-12-05 | Autolus Ltd | Antibody |
| GB201817822D0 (en) * | 2018-10-31 | 2018-12-19 | Autolus Ltd | Binding domain |
| KR20210121136A (ko) * | 2019-01-29 | 2021-10-07 | 상하이 지아오통 유니버시티 | 키메라 항원 수용체 및 그 용용 |
| CA3130754A1 (en) * | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| CN110317266A (zh) * | 2019-07-17 | 2019-10-11 | 东北农业大学 | 三种scFv抗体、其编码基因及其在制备治疗或预防O型口蹄疫病制剂中的应用 |
| WO2021188454A1 (en) * | 2020-03-16 | 2021-09-23 | Marengo Therapeutics, Inc. | Engineered cell compositions and methods of use thereof |
| GB202004263D0 (en) | 2020-03-24 | 2020-05-06 | Autolus Ltd | Antibody conjugate |
| GB202005216D0 (en) | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
| US20230133554A1 (en) | 2020-04-09 | 2023-05-04 | Autolus Limited | Molecule |
| GB202101491D0 (en) | 2021-02-03 | 2021-03-17 | Autolus Ltd | Molecule |
| WO2021217085A1 (en) * | 2020-04-24 | 2021-10-28 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| CN111537735A (zh) * | 2020-05-15 | 2020-08-14 | 江西赛基生物技术有限公司 | 抗体检测试剂盒以及在免疫分析方面的应用 |
| CN111549044B (zh) * | 2020-07-13 | 2020-10-23 | 北京市肿瘤防治研究所 | 靶向trbc1 car-t细胞的制备方法与应用 |
| US20230287345A1 (en) * | 2020-08-18 | 2023-09-14 | Medigene Immunotherapies Gmbh | ENRICHMENT OF T CELLS USING AN ANTI-Cß ANTIBODY |
| GB2616354A (en) * | 2020-08-26 | 2023-09-06 | Marengo Therapeutics Inc | Methods of detecting TRBC1 or TRBC2 |
| EP4294841A1 (en) | 2021-02-17 | 2023-12-27 | The Johns Hopkins University | Methods and materials for treating clonal t cell expansions |
| US20220267415A1 (en) * | 2021-02-17 | 2022-08-25 | The Board Of Regents Of The University Of Texas System | Multimeric sars-cov-2 binding molecules and uses thereof |
| GB202112923D0 (en) * | 2021-09-10 | 2021-10-27 | Ucl Business Ltd | Binding domain |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2088905A1 (en) * | 1990-08-09 | 1992-02-10 | Yongwon Choi | Producing monoclonal antibodies against human t-cell receptor elements using recombinant dna vectors |
| US6790604B1 (en) * | 1998-05-12 | 2004-09-14 | Stefan A. Cohen | Methods for identifying or diagnosing carcinoma cells with metastatic potential based on the measurement of lymphoid genes or their products in carcinoma cells |
| AU2003233197A1 (en) * | 2002-04-29 | 2003-11-17 | Genpat77 Pharmacogenetics Ag | Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis |
| RU2355703C2 (ru) * | 2002-10-09 | 2009-05-20 | Медиджен Лимитед | Одноцепочечные рекомбинантные т-клеточные рецепторы |
| GB0304068D0 (en) * | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| US7741045B2 (en) * | 2006-11-16 | 2010-06-22 | General Electric Company | Sequential analysis of biological samples |
| WO2009151628A2 (en) * | 2008-06-12 | 2009-12-17 | Gov't Of The Usa, As Represented By The Secretary, Department Of Health Human Services | Monitoring tcr-b to determine hiv therapy and disease progression |
| AU2009288354A1 (en) * | 2008-08-26 | 2010-03-11 | Macrogenics Inc. | T-cell receptor antibodies and methods of use thereof |
| HUE029257T2 (en) * | 2009-12-29 | 2017-02-28 | Aptevo Res And Dev Llc | Heterodimer binding proteins and their use |
| JP6000507B2 (ja) * | 2010-09-30 | 2016-09-28 | パナソニックヘルスケアホールディングス株式会社 | 診療情報登録装置 |
| MA34813B1 (fr) * | 2010-12-09 | 2014-01-02 | Univ Pennsylvania | Utilisation de lymphocytes t modifies par un recepteur chimerique d'antigenes chimerique pour traiter le cancer |
| WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| IN2014DN10991A (es) * | 2012-05-25 | 2015-09-25 | Cellectis | |
| US10443100B2 (en) * | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
| CA2959428A1 (en) * | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
| WO2016160721A1 (en) * | 2015-03-27 | 2016-10-06 | President And Fellows Of Harvard College | Modified t cells and methods of making and using the same |
-
2015
- 2015-03-05 CN CN201580011306.XA patent/CN106068276B/zh active Active
- 2015-03-05 RU RU2018140694A patent/RU2018140694A/ru unknown
- 2015-03-05 KR KR1020207006445A patent/KR102235202B1/ko active IP Right Grant
- 2015-03-05 WO PCT/GB2015/050643 patent/WO2015132598A1/en active Application Filing
- 2015-03-05 CU CU2016000129A patent/CU24475B1/es unknown
- 2015-03-05 BR BR112016020304-6A patent/BR112016020304B1/pt active IP Right Grant
- 2015-03-05 SG SG10201906461SA patent/SG10201906461SA/en unknown
- 2015-03-05 AU AU2015225944A patent/AU2015225944B2/en active Active
- 2015-03-05 CN CN202010859460.5A patent/CN112094353A/zh active Pending
- 2015-03-05 CA CA2940564A patent/CA2940564C/en active Active
- 2015-03-05 HU HUE15709319A patent/HUE047641T2/hu unknown
- 2015-03-05 PE PE2016001548A patent/PE20170125A1/es unknown
- 2015-03-05 JP JP2016554603A patent/JP6767872B2/ja active Active
- 2015-03-05 ES ES15709319T patent/ES2758173T3/es active Active
- 2015-03-05 DK DK15709319.6T patent/DK3125934T3/da active
- 2015-03-05 PT PT157093196T patent/PT3125934T/pt unknown
- 2015-03-05 MY MYPI2016703188A patent/MY173567A/en unknown
- 2015-03-05 SG SG11201606583VA patent/SG11201606583VA/en unknown
- 2015-03-05 PL PL15709319T patent/PL3125934T3/pl unknown
- 2015-03-05 RU RU2021101502A patent/RU2021101502A/ru unknown
- 2015-03-05 MX MX2016010856A patent/MX2016010856A/es active IP Right Grant
- 2015-03-05 CN CN202410891896.0A patent/CN118852462A/zh active Pending
- 2015-03-05 IL IL278878A patent/IL278878B/en unknown
- 2015-03-05 PE PE2021000759A patent/PE20211887A1/es unknown
- 2015-03-05 RU RU2016138421A patent/RU2744046C2/ru active
- 2015-03-05 EP EP17172755.5A patent/EP3241561A1/en active Pending
- 2015-03-05 KR KR1020167027423A patent/KR102088082B1/ko active IP Right Grant
- 2015-03-05 US US15/123,287 patent/US20170066827A1/en not_active Abandoned
- 2015-03-05 CN CN202010858243.4A patent/CN112094347A/zh active Pending
- 2015-03-05 EP EP15709319.6A patent/EP3125934B1/en active Active
- 2015-03-05 KR KR1020207006444A patent/KR102235201B1/ko active IP Right Grant
- 2015-03-05 SG SG10201906460PA patent/SG10201906460PA/en unknown
-
2016
- 2016-08-04 IL IL247110A patent/IL247110A0/en active IP Right Grant
- 2016-08-17 PH PH12016501646A patent/PH12016501646A1/en unknown
- 2016-08-19 MX MX2019013846A patent/MX2019013846A/es unknown
- 2016-08-19 MX MX2019013845A patent/MX2019013845A/es unknown
- 2016-09-01 CL CL2016002195A patent/CL2016002195A1/es unknown
-
2017
- 2017-05-26 US US15/606,480 patent/US20170334998A1/en not_active Abandoned
- 2017-05-31 JP JP2017107689A patent/JP6767931B2/ja active Active
-
2018
- 2018-10-30 CL CL2018003096A patent/CL2018003096A1/es unknown
-
2019
- 2019-06-07 CL CL2019001567A patent/CL2019001567A1/es unknown
- 2019-06-07 CL CL2019001568A patent/CL2019001568A1/es unknown
- 2019-07-09 AU AU2019204921A patent/AU2019204921C1/en active Active
- 2019-07-09 AU AU2019204925A patent/AU2019204925B2/en active Active
-
2020
- 2020-03-25 JP JP2020054667A patent/JP7149304B2/ja active Active
- 2020-04-01 PH PH12020550203A patent/PH12020550203A1/en unknown
- 2020-11-22 IL IL278879A patent/IL278879A/en unknown
-
2021
- 2021-09-15 JP JP2021150189A patent/JP2021184773A/ja not_active Withdrawn
-
2024
- 2024-04-03 JP JP2024060080A patent/JP2024074907A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211887A1 (es) | Receptor antigenico quimerico (car) que comprende un dominio de union a antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t | |
| PE20190120A1 (es) | Moleculas de union a bcma y metodos de uso de las mismas | |
| MX2016010643A (es) | Receptor antigenico quimerico. | |
| AR111418A1 (es) | Dominios de unión a antígeno humanizados y métodos de uso | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| CO2018013500A2 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| PE20191031A1 (es) | ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| PH12019502785A1 (en) | Anti trbc1 antigen binding domains | |
| CY1121158T1 (el) | Αντισωμα ικανο να αναγνωριζει ειδικα υποδοχεα τρανσφερρινης | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
| PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
| MX2018016364A (es) | Anticuerpos anti-pd-l1. | |
| TR201909647T4 (tr) | Bir cd-19 bağlama alanı içeren kimerik antijen reseptörü (car). | |
| AR114284A1 (es) | Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl | |
| PE20191102A1 (es) | Anticuerpos anti-pd-1 y sus usos | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
| EA201990331A1 (ru) | Мультиспецифические антигенсвязывающие белки и способы их применения | |
| PE20190356A1 (es) | Receptores quimericos y metodos de uso de los mismos | |
| NZ728749A (en) | Anti-pd-l1 antibodies | |
| PE20200734A1 (es) | Anticuerpos anti-tgf-beta y su uso | |
| WO2015127136A3 (en) | Ebola monoclonal antibodies |